Acalabrutinib is not chemotherapy. It is a targeted therapy, a newer class of cancer treatment that works differently from traditional chemotherapy at a fundamental level. Sold under the brand name Calquence, acalabrutinib is classified by the FDA as a kinase inhibitor, and it is now a preferred first-line treatment for chronic lymphocytic leukemia (CLL).
How Acalabrutinib Differs From Chemotherapy
Chemotherapy kills all fast-growing cells in the body, cancerous or not. That broad approach is why it causes familiar side effects like hair loss, severe nausea, and damage to healthy tissues in the gut, mouth, and bone marrow.
Acalabrutinib works by blocking a single protein called Bruton tyrosine kinase (BTK) that certain cancer cells need to survive and multiply. It forms a permanent bond with this protein inside the cancer cell, shutting down the signaling pathway that tells the cell to keep growing. Because it targets one specific protein rather than attacking all rapidly dividing cells, it largely spares healthy tissue. The National Cancer Institute draws this distinction clearly: targeted therapies interfere with specific proteins that help tumors grow and spread, while chemotherapy kills all cells that grow and divide quickly.
Why the Confusion Exists
Many people use “chemotherapy” as a catch-all term for any cancer drug. Doctors sometimes contribute to this by referring to any anti-cancer medication regimen as “chemo.” But in oncology, the categories matter because they predict what the treatment experience will look like. Acalabrutinib belongs to the targeted therapy category alongside other BTK inhibitors. It is taken as an oral capsule, typically twice daily, and treatment continues as long as it keeps working. There are no infusion sessions, no cycles with planned recovery weeks, and no pre-medications to manage severe nausea.
What Acalabrutinib Treats
Acalabrutinib is FDA-approved for CLL, the most common type of leukemia in adults. Current NCCN guidelines list it as a preferred first-line regimen for CLL, meaning it is recommended before chemotherapy is even considered. It can be used alone or combined with obinutuzumab, an antibody-based therapy.
In a major clinical trial called ELEVATE-TN, patients who received acalabrutinib with obinutuzumab had dramatically better outcomes than those who received a chemotherapy-based regimen. At six years of follow-up, 78% of patients in the acalabrutinib-obinutuzumab group had not seen their disease progress, compared to just 17.2% in the chemotherapy group. Even acalabrutinib alone outperformed chemotherapy, with a 61.5% progression-free rate at six years.
Chemotherapy is now generally reserved for patients whose disease has stopped responding to targeted therapies, not as a starting treatment.
Side Effects Compared to Chemotherapy
Acalabrutinib does not cause many of the side effects people associate with chemotherapy. Hair loss, severe vomiting, and mouth sores from destroyed mucosal tissue are hallmarks of traditional chemo that acalabrutinib typically does not produce.
That said, acalabrutinib has its own side effect profile. The most common issues include headache, diarrhea, muscle and joint pain, bruising, and upper respiratory symptoms like a runny nose or sore throat. Bleeding-related effects are particularly worth knowing about: easy bruising, nosebleeds, and prolonged bleeding from cuts occur because BTK plays a role in platelet function. Some people experience heart rhythm changes, including a fast or irregular heartbeat. Rash and fatigue are also reported.
These side effects are generally milder and more manageable than what chemotherapy produces, but they are not trivial. Because treatment is continuous rather than given in limited cycles, side effects can persist for as long as you take the drug.
Practical Considerations for Taking It
Acalabrutinib is a capsule you take at home, which is a significant quality-of-life difference from chemotherapy infusions that require hours at a treatment center. The standard regimen is one capsule twice a day, roughly 12 hours apart.
One important interaction to be aware of: acid-reducing medications dramatically lower how much acalabrutinib your body absorbs. Proton pump inhibitors like omeprazole reduce absorption by roughly 57%, and common antacids like calcium carbonate reduce it by about 53%. If you need an antacid, separating the doses by at least two hours helps minimize this effect. Proton pump inhibitors are harder to work around because their acid-suppressing effects last all day, so your doctor may need to find alternatives for heartburn or reflux management while you’re on treatment.
Where It Fits in Cancer Treatment
Acalabrutinib belongs to a generation of cancer drugs that have fundamentally changed how blood cancers are treated. For CLL in particular, targeted therapies like acalabrutinib have largely replaced chemotherapy as the standard approach. Patients starting treatment today are far more likely to be prescribed a BTK inhibitor than a chemotherapy regimen, and the clinical data supports that shift with significantly better long-term disease control and a more tolerable treatment experience.